$110,877,385
to MAPP BIOPHARMACEUTICAL, INC.
THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION.
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Latest obligation on a 2022 contract to develop MBP091, an immunotherapy for treating Marburg virus infection.
Marburg is a rare but highly lethal hemorrhagic fever. This therapeutic addresses a critical gap in medical countermeasures for emerging infectious disease threats.
Signals sustained federal investment in specialized biopharmaceutical manufacturing and clinical-stage immunotherapy production capacity.
Biodefense and pandemic-preparedness therapeutics are strategic priorities; U.S. development of novel antivirals reduces dependence on foreign sources for outbreak response.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-27. Cost: $0.003068.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50122C00076_7505_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.